Atossa Therapeutics, Inc.
ATOS
$1.88
$0.116.22%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 31.49% | 18.15% | 9.92% | 2.78% | -1.14% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 41.14% | 34.47% | 11.42% | -1.90% | -10.25% |
| Operating Income | -41.14% | -34.47% | -11.42% | 1.90% | 10.25% |
| Income Before Tax | -42.88% | -36.33% | -12.15% | -10.84% | 11.27% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -42.88% | -36.33% | -12.15% | -10.84% | 11.27% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -42.88% | -36.33% | -12.15% | -10.84% | 11.27% |
| EBIT | -41.14% | -34.47% | -11.42% | 1.90% | 10.25% |
| EBITDA | -41.16% | -34.49% | -11.47% | 1.87% | 10.23% |
| EPS Basic | -40.27% | -32.80% | -9.41% | -8.88% | 11.98% |
| Normalized Basic EPS | -50.10% | -42.36% | -16.82% | -2.31% | 8.59% |
| EPS Diluted | -40.27% | -32.80% | -9.41% | -8.88% | 11.98% |
| Normalized Diluted EPS | -50.10% | -42.36% | -16.82% | -2.31% | 8.59% |
| Average Basic Shares Outstanding | 1.85% | 2.66% | 2.42% | 1.74% | 0.88% |
| Average Diluted Shares Outstanding | 1.85% | 2.66% | 2.42% | 1.74% | 0.88% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |